PA-25-169-Full-Announcement.html

This is a Full Announcement document for PA-25-169, the Trailblazer Award for New and Early Stage Investigators (R21 Clinical Trial Optional), issued by the Department of Health and Human Services National Institutes of Health. The opportunity supports research programs that integrate engineering and physical sciences with life/biomedical sciences, targeting NIH-defined New and Early Stage Investigators. The funding is available through three CFDA programs: Discovery and Applied Research for Technological Innovations (93.286), Aging Research (93.866), and Vision Research (93.867).

A distinctive feature of this R21 grant is that preliminary data are not required, expected, or encouraged. If included, preliminary data must be limited to one-half page with a maximum of one figure, and any applications exceeding these limits will be deemed non-compliant. Projects may be exploratory, developmental, proof of concept, or high risk-high impact, and can be technology design-directed, discovery-driven, or hypothesis-driven. The opportunity is open to a wide range of applicants including higher education institutions, nonprofits, government entities, tribal organizations, and small businesses.